Equillium, Inc. (EQ): Cash & Equivalents
$30.28M
As of 2025-12-31
$57.16M
As of 2026-06-30
-20.0%
3-year compound annual growth
+4.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.28M | +67.4% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $18.09M | -22.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $23.22M | -60.7% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $59.11M | +17.4% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $50.37M | +110.0% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $23.98M | +81.4% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $13.22M | -53.6% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $28.51M | +301.3% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $7.10M | n/a | 2019-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Equillium, Inc. (EQ) | 2025-12-31 | $30.28M | +67.4% |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $31.63M | +70.7% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $20.73M | -34.4% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $12.64M | +531.6% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $345.1K | -44.9% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $26.71M | -35.9% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
Compare EQ, NVCT, TVRD, VBIO side by side · Screen every company in Pharmaceutical Preparations ↗